# TATEN (NCT04251169)

> Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus paclitaxel
- Indication: HR+/HER2- non-luminal advanced breast cancer after CDK4/6-inhibitor progression

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04251169
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: SOLTI Breast Cancer Research Group
- Conditions: Metastatic Breast Cancer
- Interventions: Pembrolizumab; Paclitaxel
- Enrollment: 20
- Primary outcome: Overall Response Rate of Pembrolizumab in Combination With Paclitaxel in HR+/HER2- Non-luminal Subtype Advanced Breast Cancer Defined by the PAM50 Assay

## Indexed commentary on TATEN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=taten-nct04251169